Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
US-2024350630-A1 · Oct 24, 2024 · US
Haploid human embryonic stem cell lines and somatic cell lines and methods of making the same
US10961503B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10961503-B2 |
| Application number | US-201615747103-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 28, 2016 |
| Priority date | Jul 29, 2015 |
| Publication date | Mar 30, 2021 |
| Grant date | Mar 30, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Haploid human embryonic stem cells and cell lines, haploid multipotent human cells, and haploid differentiated human cells are provided. In addition, methods of making and using the haploid human cells are provided.
First claim
Opening claim text (preview).
The invention claimed is: 1. An enriched population of haploid human embryonic stem (ES) cells, wherein said population is capable of differentiating into a terminally differentiated haploid cell selected from a haploid mature neuron, and a haploid cardiomyocyte. 2. The enriched population of claim 1 , comprising at least 5% haploid human ES cells. 3. The enriched population of claim 1 , comprising at least 95% haploid human ES cells. 4. The enriched population of claim 1 , wherein the enriched population is in human embryonic stem cell media. 5. The enriched population of claim 1 , wherein said enriched population is derived from an artificially activated human oocyte. 6. The enriched population of claim 1 , wherein said haploid human ES cells maintain pluripotentency in culture of at least 3 passages. 7. The enriched population of claim 1 , wherein said haploid human ES cells maintain a haploid karyotype in culture of at least 3 passages. 8. The enriched population of claim 1 , comprising at least 1 million haploid human ES cells. 9. A human ES cell line comprising the enriched population of claim 1 .
Assignees
Inventors
Classifications
Conditioning of cells for in vitro fecondation or nuclear transfer · CPC title
Cells produced using nuclear transfer · CPC title
from germ cells · CPC title
Small molecules not provided for elsewhere · CPC title
Kinases (EC 2.7.) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10961503B2 cover?
- Haploid human embryonic stem cells and cell lines, haploid multipotent human cells, and haploid differentiated human cells are provided. In addition, methods of making and using the haploid human cells are provided.
- Who is the assignee on this patent?
- New York Stem Cell Found Inc, Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0606. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).